Compare Public Storage (PSA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs TG Therapeutics Inc — how do they compare? Public Storage trades at $289.86 (market cap $53.35B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Public Storage is far larger — about 6.5× TG Therapeutics Inc's market cap, and Public Storage pays a 4.2% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Public Storage for 130 Days and TG Therapeutics Inc for 16 Days on average.
| PSA | TGTX | |
|---|---|---|
Market Cap | $53.35B | $8.16B |
Volume | 1,176,034 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $330.47 | $59.06 |
52-Week Low | $258.44 | $26.94 |
Typical Hold Time | 130 Days | 16 Days |
Enterprise Value | $67.62B | $8.37B |
Dividend Yield | 4.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $289.86, up 2.79% today, showing strong profitability with 41.8% net income margin and consistent earnings beats in recent quarters. The stock faces technical headwinds with a bearish moving average signal, trading near resistance at $291. Recent developments include the completion of the Public Storage Canada acquisition and a $400 million Canadian bond offering, positioning for growth despite mixed analyst sentiment.
PSA offers a compelling value proposition with robust fundamentals and a 4.05% dividend yield, though elevated valuation ratios and technical resistance near current levels suggest near-term consolidation. Upside potential exists toward the $328 consensus target, but investors should monitor same-store revenue growth trends and interest rate sensitivity given the REIT structure.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
